Plasma Protease C1-inhibitor Market Size Worth US$ 7.96 Billion By 2032 | CAGR: 9.6%

The global plasma protease C1-inhibitor market size is expected to reach USD 7.96 billion by 2032, according to a new study by Polaris Market Research. The report “Global Plasma Protease C1-inhibitor Market Size, Share, Trends, Industry Analysis Report: By Drug Class (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor), Dosage Form, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2024 - 2032.” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market for plasma protease C1-inhibitor (C1-INH) has witnessed substantial innovation in recent years, driven by advancements in formulation, safety, therapeutic efficacy, and expanded indications. The shift from intravenous to subcutaneous administration represents a significant leap forward, offering improved convenience and potentially enhancing patient compliance. Concurrently, improvements in purification processes have bolstered the safety profiles of C1-INH products, minimized adverse reactions and maximizing therapeutic effectiveness.

Ongoing research into novel mechanisms of action beyond traditional C1-INH replacement therapy holds promise for broadening treatment options, potentially catering to a wider range of patients with hereditary angioedema (HAE) and related conditions. For instance, in June 2024, two new medicines, donidalorsen and sebetralstat, showed promising results in treating hereditary angioedema, as reported by an internist and researcher from Amsterdam UMC.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market/request-for-sample

The market for plasma protease C1-inhibitor (C1-INH) is characterized by a rising demand driven by increasing diagnoses of HAE globally. This rare genetic disorder necessitates effective C1-INH replacement therapies, prompting ongoing advancements in treatment options. Innovations in delivery methods and formulations aim to enhance patient convenience and adherence, while geographic expansion efforts seek to improve access to these specialized therapies worldwide. The competitive landscape remains active with pharmaceutical companies investing in research and development, supported by regulatory initiatives that facilitate market growth and adoption of new therapies. Patient-centric programs and advocacy efforts further contribute to improving outcomes and quality of life for individuals living with HAE, shaping the future trajectory of the C1-INH market.

Plasma Protease C1-inhibitor Market Report Highlights

• C1-inhibitors led the market in 2023, with selective bradykinin B2 receptor antagonists expected to show the fastest growth due to ongoing R&D efforts by key industry players.
• Lyophilized segments dominated the market with their stability, extended shelf life, and convenient storage and transport, making them favored for C1-inhibitor therapy, ensuring effectiveness and ease for patients and providers.
• Hospital pharmacies led the plasma protease C1-inhibitor market due to their wide accessibility, regulatory adherence, and effective management of specialized therapies such as plasma protease C1-inhibitor.
• North America led the market in 2023, owing to its substantial healthcare spending, advanced infrastructure, extensive research, and significant use of plasma protease C1-inhibitor therapies for rare diseases such as hereditary angioedema.
• The global key plasma protease C1-inhibitor market players include BioCryst Pharmaceuticals, Inc.; CENTOGENE N.V.; CSL; Fresenius Kabi; Ionis Pharmaceuticals, Inc.; KalVista Pharmaceuticals; Pharming; Sanquin; Shire plc; and Takeda Pharmaceutical Company Limited.

Polaris Market Research has segmented the Plasma Protease C1-inhibitor market report based on drug class, dosage form, distribution channel, and region:

By Drug Class Outlook (Revenue - USD billion, 2019 - 2032)

• C1-inhibitors

• C1-esterase Inhibitor
• Recombinant Inhibitor

• Kallikrein Inhibitor
• Selective Bradykinin B2 Receptor Antagonist

By Dosage Form Outlook (Revenue - USD billion, 2019 - 2032)

• Lyphophlised
• Injectables

By Distribution Channel Outlook (Revenue - USD billion, 2019 - 2032)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Regional Outlook (Revenue - USD billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Vietnam
• Rest of Asia Pacific

• Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa

Plasma Protease C1-inhibitor Report Scope